TACE AS BRIDGE TO
LIVER TRANSPLANT
TACE prevents HCC progression during the liver transplant waiting period β maintaining patients within Milan criteria, reducing waitlist dropout, and in complete responders, offering the possibility of complete pathological necrosis of the tumour at explantation.
analyticsAt a Glance
- check_circleWaitlist dropout from HCC progression occurs in 15β30% of patients over 6β12 months without bridging therapy
- check_circleTACE reduces dropout rates to 5β15% in most published series across different waiting list durations
- check_circleMilan criteria: single nodule β€5 cm, or β€3 nodules all β€3 cm β bridging TACE is used to maintain or achieve these thresholds
- check_circleComplete pathological necrosis at explant is documented in 15β30% of TACE-bridged tumours β associated with excellent post-transplant survival
Why Bridging Therapy Is Essential During Liver Transplant Waiting
Liver transplantation is the only treatment that simultaneously removes the HCC and the cirrhotic liver that creates the HCC risk field β offering a curative outcome for selected patients. However, organ shortages mean waiting times of 6β24 months are common in most transplant programmes. During this period, HCC can progress beyond Milan criteria β the established size and number thresholds beyond which transplant outcomes worsen significantly β causing patients to be removed from the waiting list (dropout).
βEvery month on the transplant waiting list is a month in which untreated HCC can grow from within criteria to beyond criteria. TACE bridging buys the time the waiting list system cannot give patients β by keeping the tumour controlled while an organ becomes available.β
Milan Criteria: The Transplant Eligibility Threshold
The Milan criteria (Mazzaferro 1996) define transplant eligibility for HCC: a single nodule β€5 cm, OR up to three nodules all β€3 cm, with no macrovascular invasion or extrahepatic spread. Within these criteria, 5-year post-transplant survival exceeds 70% with recurrence rates below 15%. Beyond Milan, outcomes worsen substantially β which is why maintaining disease within Milan during waiting is the primary goal of bridging therapy.
Waitlist Dropout Without Bridging
In series without active bridging, dropout rates of 15β30% over 12 months have been documented β meaning a significant proportion of patients who were eligible at listing become ineligible due to tumour progression before a donor organ becomes available. Bridging therapy substantially reduces but does not eliminate dropout β the residual dropout under TACE reflects new lesion emergence and non-target progression that bridging cannot address.
TACE Bridge Therapy: Dropout Reduction and Pathological Response Data
Published series consistently show TACE reduces waitlist dropout and achieves complete pathological necrosis in a meaningful proportion of bridged tumours.
Waitlist Dropout Rate: With vs Without TACE Bridging
Pooled from Ravaioli et al., Golfieri et al., and US OPTN/UNOS registry data; rates vary by waiting time and programme
- Dropout rate without bridging at 12 months15β30%
- Dropout rate with TACE bridging at 12 months5β15%
- Dropout rate with TACE bridging at 6 months3β8%
Pathological Complete Necrosis at Explant After TACE Bridge
Percentage of explanted livers showing complete pathological necrosis of HCC nodules after TACE bridge; varies by technique, number of sessions, and tumour characteristics
- Complete pathological necrosis: cTACE bridge15β25%
- Complete pathological necrosis: DEB-TACE bridge20β30%
- Post-transplant 5-year survival: complete necrosis>80%
- Post-transplant 5-year survival: viable residual HCC65β70%
How TACE Bridge Therapy Is Conducted: The Clinical Protocol
TACE as bridging therapy follows a specific protocol designed to maximise locoregional control while preserving liver function for post-transplant recovery.
| Protocol Element | Standard Approach | Rationale |
|---|---|---|
| First TACE timing | Within 3 months of transplant listing β earlier if high-risk tumours or PSADT <6 months | Early intervention prevents progression to beyond-Milan during waiting; PSADT (tumour doubling time on AFP/imaging) guides urgency |
| Target of TACE | All viable HCC nodules within Milan criteria β not just the largest lesion | Complete locoregional control of all nodules reduces dropout and optimises complete necrosis at explant |
| Response assessment interval | Contrast-enhanced MRI at 4β6 weeks post-each session | mRECIST criteria: assess arterial enhancement of each nodule; identifies complete response vs residual viable tumour requiring retreatment |
| Retreatment decision | On-demand TACE β retreat when viable tumour is identified on follow-up MRI | 'On-demand' protocol (rather than scheduled repeat) is now evidence-preferred over fixed-interval TACE (Vilana et al.; Hatanaka et al.) |
| Maximum sessions | No defined maximum β guided by liver function and tumour response | Cumulative TACE can cause liver fibrosis and function decline β Child-Pugh reassessment before each session is mandatory |
| Bridging for downstaging | TACE used to reduce tumour burden from beyond-Milan to within-Milan for relisting | UNOS downstaging protocol allows relisting if tumour responds to within-Milan criteria; 3β6 month observation required after downstaging |
| Pre-transplant imaging | Final MRI within 4β6 weeks of transplant β last imaging assessment before surgery | Confirms current tumour status; identifies any new lesions; updated Milan staging before organ allocation |
TACE for Downstaging: Expanding Transplant Eligibility Beyond Milan
TACE is not only used to maintain patients within Milan criteria β it is also used to actively reduce tumour burden in patients who present beyond Milan, potentially making them transplant candidates through 'downstaging'.
The UNOS Downstaging Protocol
The United Network for Organ Sharing (UNOS) in the US established a formal downstaging protocol allowing patients with tumours beyond Milan but within specified limits (single lesion >5 cm and β€8 cm; 2β3 lesions with at least one >3 cm and all β€5 cm; 4β5 lesions all β€3 cm) to be listed for transplant if TACE (or ablation) reduces the tumour burden to within Milan criteria, with a minimum 3-month observation period showing stable response. This protocol has been shown to achieve good post-transplant outcomes comparable to patients listed within Milan.
Evidence for Downstaging Success
The UCSF downstaging study (Mehta et al.) reported that approximately 70% of appropriately selected patients achieve successful downstaging to within Milan with locoregional therapy β predominantly TACE. Post-transplant 5-year survival in successful downstagees (72%) was comparable to patients listed within Milan (68%), supporting downstaging as a valid expansion of transplant eligibility.
When Downstaging Is Not Appropriate
Downstaging is not appropriate for all patients beyond Milan. Contraindications include: tumour burden too extensive for the UNOS downstaging protocol (e.g. diffuse HCC or portal vein invasion); biology suggesting rapidly aggressive disease (AFP >1,000 ng/mL with rising trajectory); extrahepatic spread; or Child-Pugh decompensation incompatible with waiting for a response period.
TACE Bridge Therapy: Key Numbers
Reference figures from the published literature on TACE as bridge to transplant.
- 15β30%Waitlist dropout without bridging at 12 monthsThe baseline risk of disease progression leading to delisting β the primary problem TACE bridge therapy addresses.
- 5β15%Waitlist dropout with TACE bridging at 12 monthsThe risk reduction TACE bridging achieves β a 50β70% relative reduction in dropout events versus no bridging.
- 20β30%Rate of complete pathological necrosis at explant after TACEThe proportion of TACE-bridged tumours showing no viable cancer cells at the time of transplantation β associated with excellent post-transplant prognosis.
- 70%5-year post-transplant survival within Milan criteriaThe outcome benchmark that Milan criteria were designed to select for β Mazzaferro's original 1996 data have held up remarkably well over nearly 30 years of follow-up.
More from the TACE Resource Library
Continue exploring TACE β from the basics and technique comparison to survival data and access in China.
- What Is TACE? A Patient Introduction to Liver Cancer Embolisation
- cTACE vs DEB-TACE: Which Technique Is Right for Your HCC?
- TACE Patient Selection: BCLC Staging and Child-Pugh Score
- TACE Survival Data: Evidence from Pivotal Clinical Trials
- TACE Therapy β Complete Treatment Guide
- Liver Transplantation for HCC: Milan Criteria and Beyond
Frequently Asked Questions
Common questions from HCC patients on the transplant waiting list receiving TACE bridge therapy.
About TACE Bridge to Transplant
If my TACE shows complete response, do I still need a transplant?
A complete response to TACE on imaging does not eliminate the need for transplant in patients with underlying cirrhosis. The cirrhotic liver remains at risk of developing new HCC nodules β the risk field is not addressed by TACE. Complete imaging response means the treated tumour(s) show no viable enhancement, but this does not guarantee complete pathological necrosis (microscopically there may be residual viable cells), and new lesions can emerge elsewhere in the cirrhotic liver. Transplantation remains the only treatment that removes both the tumour and the cirrhotic risk field simultaneously. Continued waitlist management and interval imaging are essential regardless of TACE response.
My tumour has grown slightly on the waiting list despite TACE β am I about to be removed from the list?
Slight growth on TACE does not automatically mean delisting. The transplant team assesses whether the tumour remains within Milan criteria at the time of reassessment β not whether it has grown from the pre-TACE baseline. If tumour growth means the lesion has exceeded 5 cm (single lesion) or any nodule now exceeds 3 cm (multiple lesions), a further TACE session may be scheduled to regain control within criteria. Criteria compliance at the time of organ offer β not necessarily the trend during waiting β is the primary concern. Discuss the specific numbers (current largest lesion size, total nodule count) with your transplant hepatologist to understand exactly how close or far you are from the Milan threshold.
Can I be downstaged from beyond Milan to within Milan with TACE in China?
Yes β Chinese transplant centres follow UNOS-compatible downstaging protocols, and TACE for downstaging is routinely performed at major hepatobiliary programmes. The key requirements are the same as in Western programmes: initial tumour burden must fall within the UNOS downstaging protocol eligibility range; TACE must achieve reduction to within Milan criteria on imaging; a minimum observation period (typically 3β6 months) is required to confirm stability; and final imaging before listing must show sustained within-Milan status. CancerFax can connect you with specialist transplant hepatology and interventional radiology teams in China who manage the complete TACE downstaging to transplant pathway.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
On the Transplant Waiting List with HCC?
CancerFax can connect you with specialist hepatobiliary teams in China and India who perform TACE bridging as part of integrated liver transplant programmes β coordinating waitlist management, TACE sessions, and transplant evaluation from a single multidisciplinary team.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.